ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,631.22
0.28%
Dow Jones
40,211.72
0.53%
US Dollar vs MXN
17.74788
0.10%
Brent Oil
83.56
-0.92%
Bitcoin
63,519.48
-2.05%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Acceleron Pharma Inc (XLRN)

  7. Acceleron Pharma Inc (XLRN) Noticias

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
16/10/201806:00Business WireAcceleron to Host Pulmonary Arterial Hypertension Research and Development Deep Dive Event on November 16, 2018 in New York C...NASDAQ:XLRNAcceleron Pharma Inc
10/10/201810:39Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XLRNAcceleron Pharma Inc
27/09/201806:00Business WireAcceleron Announces Presentations on ACE-083 at the 23rd International Annual Congress of the World Muscle SocietyNASDAQ:XLRNAcceleron Pharma Inc
04/09/201813:43Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:XLRNAcceleron Pharma Inc
04/09/201806:00Business WireAcceleron to Participate in Three Upcoming Healthcare Investor ConferencesNASDAQ:XLRNAcceleron Pharma Inc
31/08/201818:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
02/08/201815:27Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
02/08/201815:21Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
02/08/201815:05Business WireAcceleron Reports Second Quarter 2018 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
26/07/201806:00Business WireAcceleron to Webcast Second Quarter 2018 Operating and Financial Results on August 2, 2018NASDAQ:XLRNAcceleron Pharma Inc
23/07/201806:00Business WireAcceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease...NASDAQ:XLRNAcceleron Pharma Inc
12/07/201806:00Business WireAcceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular DystrophyNASDAQ:XLRNAcceleron Pharma Inc
10/07/201816:28Dow Jones NewsHealth Care Shares Move Higher as Focus Shifts to Earnings -- Health Care RoundupNASDAQ:XLRNAcceleron Pharma Inc
09/07/201817:36Dow Jones NewsCelgene, Acceleron Say Trial on Blood-Disorder Drug Yields Positive Results -- UpdateNASDAQ:XLRNAcceleron Pharma Inc
09/07/201817:20Dow Jones NewsCelgene and Acceleron Announce Positive Results From Blood-Disorder Drug TrialsNASDAQ:XLRNAcceleron Pharma Inc
09/07/201815:52Business WireCelgene & Acceleron Announce Luspatercept Achieved Primary & All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in ...NASDAQ:XLRNAcceleron Pharma Inc
05/07/201815:46Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
05/07/201815:30Business WireAcceleron Appoints Robert K. Zeldin, M.D., Chief Medical OfficerNASDAQ:XLRNAcceleron Pharma Inc
28/06/201815:30Business WireCelgene & Acceleron Announce Luspatercept Achieved Primary & Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Pat...NASDAQ:XLRNAcceleron Pharma Inc
26/06/201806:00Business WireAcceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve SocietyNASDAQ:XLRNAcceleron Pharma Inc
15/06/201806:00Business WireAcceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of t...NASDAQ:XLRNAcceleron Pharma Inc
04/06/201806:00Business WireAcceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018...NASDAQ:XLRNAcceleron Pharma Inc
22/05/201806:00Business WireAcceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial HypertensionNASDAQ:XLRNAcceleron Pharma Inc
17/05/201808:21Business WireAcceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology AssociationNASDAQ:XLRNAcceleron Pharma Inc
08/05/201815:01Business WireAcceleron Reports First Quarter 2018 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
02/05/201806:00Business WireAcceleron to Participate in Two Healthcare Investor Conferences in MayNASDAQ:XLRNAcceleron Pharma Inc
01/05/201806:00Business WireAcceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD)NASDAQ:XLRNAcceleron Pharma Inc
30/04/201806:00Business WireAcceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018NASDAQ:XLRNAcceleron Pharma Inc
26/04/201807:00Business WireAcceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual MeetingNASDAQ:XLRNAcceleron Pharma Inc
26/04/201806:00Business WireAcceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology An...NASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN

Su Consulta Reciente

CCOM
SILVER
SILVER
CCOM
OILBRENT
Brent Oil
FX
EURUSD
Euro vs US Dollar
NYSE
AXP
American Express
NYSE
CVX
Chevron
CCOM
US30
US 30
NYSE
VZ
Verizon Communications
COIN
BTCUSD
Bitcoin
USI
USTECH100
US Tech 100
AMEX
SPY
SPDR S&P 500
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
MSFT
Microsoft
NASDAQ
NVDA
NVIDIA
SPI
SP500
S&P 500
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados